6623-81-0

Basic information

• Product Name: 5-Methoxy-2,4-pyrimidinediol
• Synonyms: 5-Methoxypyrimidine-2,4(1H,3H)-dione;mo5Ura;NSC 55452;5-Methoxypyrimidine-2,4-dione;3h)-pyrimidinedione,5-methoxy-4(1h;5-Methoxy-1H-pyrimidine-2,4-dione;2,4-DIHYDROXY-5-METHOXYPYRIMIDINE;2,4(1H,3H)-PYRIMIDINEDIONE, 5-METHOXY-
• CAS NO: 6623-81-0
• Molecular Formula: C₅H₆N₂O₃
• Molecular Weight: 142.11
• EINECS: 229-580-5
• Product Categories: Heterocycle-Pyrimidine series;PYRIMIDINE;APIs & Intermediate;various pyrimidines;Pyrimidines
• Mol File: 6623-81-0.mol

Chemical Properties

• Melting Point: 344°C(lit.)
• Boiling Point: 508.5oC at 760 mmHg
• Flash Point: 207.7oC
• Appearance: Beige powder
• Density: 1.39 g/cm³
• Vapor Pressure: 1.85E-10mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly, Heated), Water (Slightly, Heated)
• PKA: 8.17±0.10(Predicted)
• CAS DataBase Reference: 5-Methoxy-2,4-pyrimidinediol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxy-2,4-pyrimidinediol(6623-81-0)
• EPA Substance Registry System: 5-Methoxy-2,4-pyrimidinediol(6623-81-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 6623-81-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
5-Methoxy-2,4-pyrimidinediol is used as a building block in chemical synthesis for the development of various compounds and molecules. Its unique structure and functional groups make it a valuable intermediate in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
5-Methoxy-2,4-pyrimidinediol is used in the preparation of nucleosides, which are essential components of nucleic acids. Nucleosides play a crucial role in the storage and transmission of genetic information in living organisms. 5-Methoxy-2,4-pyrimidinediol's involvement in nucleoside synthesis makes it an important constituent in the development of pharmaceutical products, particularly those targeting genetic disorders and diseases.
Used in the Preparation of 5-Methoxyuracil:
5-Methoxyuracil, also known as Fluorouracil EP Impurity D, is a methoxylated uracil derivative used in the preparation of nucleosides. 5-Methoxy-2,4-pyrimidinediol serves as a key precursor in the synthesis of 5-Methoxyuracil, further emphasizing its importance in the pharmaceutical and chemical industries.

InChI:InChI=1/C17H15ClO4/c18-13-7-12-10-3-1-2-4-11(10)17(20)21-14(12)8-15(13)22-16(19)9-5-6-9/h7-9H,1-6H2

Upstream product

• 1671-09-6 2-methanesulfonyl-5-methoxypyrimidine 
• 6290-49-9 methyl methoxyacetate 
• 57-13-6 urea 
• 109-94-4 formic acid ethyl ester 
• 107-31-3 Methyl formate 
• 50-00-0 formaldehyd 
• 66-22-8 uracil 
• 6939-11-3 mercapto-2 hydroxy-4 methoxy-5 pyrimidine 
• 6939-11-3 5-methoxy-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone 
• 104151-54-4 3-hydroxy-2-methoxyacrylic acid methyl ester sodium salt 

Downstream Products

• 19646-07-2 2,4-dichloro-5-methoxypyrimidine 
• 37805-86-0 5-methoxyuridine 2',3',5'-tri-O-benzoate 
• 1613530-29-2 C₃₃H₂₇N₅O₉ 
• 1613530-30-5 C₃₁H₂₇N₃O₉ 
• 37805-90-6 5-methoxycytidine 
• 199444-55-8 3-Benzyl-5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrimidine-2,4-dione 
• 22536-65-8 2-chloro-5-methoxy-pyrimidine 
• 1313718-71-6 4-(5-methoxy-4-morpholin-4-ylpyrimidin-2-yl)benzene-1,2-diamine 
• 1313718-69-2 4-(5-methoxy-4-morpholin-4-ylpyrimidin-2-yl)-2-nitrophenylamine 
• 1313718-44-3 4-[5-methoxy-2-(3-nitrophenyl)pyrimidin-4-yl]morpholine 

Relevant articles and documents

Preparation method of 2-chloro-5-methoxypyrimidine

The invention relates to the field of compound preparation methods, and in particular relates to a preparation method of 2-chloro-5-methoxypyrimidine, which is prepared by taking methyl methoxyacetateas a raw material. The product prepared by the preparation method has high purity, the catalyst and the solvent can be recycled, the reaction is mild, the control is easy, and the method is suitablefor industrial production.

NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS

The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Falcipain inhibitors: Optimization studies of the 2-pyrimidinecarbonitrile lead series

Falcipain-2 and falcipain-3 are papain-family cysteine proteases of the malaria parasite Plasmodium falciparum that are responsible for host hemoglobin hydrolysis to provide amino acids for parasite protein synthesis. Different heteroarylnitrile derivatives were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2- cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified, with activity against cultured parasites in the micromolar range. Introduction of protonable amines within lead molecules led to marked improvements of up to 1000 times in activity against cultured parasites without noteworthy alterations in other SAR tendencies. Optimized compounds presented enzymatic activities in the picomolar to low nanomolar range and antiparasitic activities in the low nanomolar range.

Experimental measurement and correlation of the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane at temperatures between (295 and 320) K

The solid-liquid equilibrium of 2,4-dichloro-5-methoxypyrimidine was first determined in this article. Using a laser monitoring observation technique, the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane have been determined experimentally from (295.60 to 316.39, 302.37 to 316.95, 299.44 to 316.61, 297.35 to 311.37, 298.60 to 312.15, and 298.10 to 320.08) K, respectively. The results are correlated with λ-h equation and Apelblat equation. The calculated results show that the correlation of the Apelblat model for six measured systems has less deviation than that of the λ-h equation.

ANTHRANILAMIDE INHIBITORS OF AURORA KINASE

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

Reactions of benzonitrile oxide with methoxypyrimidines and pyrimidones

Methoxypyrimidines preferentially add to benzonitrile oxide to give cycloadducts to their C=N double bonds. These, however, lose benzonitrile affording the corresponding pyrimidones. Cycloadditions to their C=C double bonds take place to a very low extent, and products generally undergo a ring opening process which affords the corresponding oximes. Pyrimidones preferentially give addition products to their nitrogen atoms, and only in the case of 4-pyrimidone, the cycloadduct to its C=C double bond was isolated.

Phenylation of pyrimidinones using diphenyliodonium salts

Pyrimidinones 1 have been phenylated under basic conditions using diphenyliodonium salts, and the effect of substituents on the yield and regiochemistry has been studied. The Royal Society of Chemistry 1999.

Simultaneous determination of five oxidative DNA lesions in human urine

A method, involving a HPLC prepurification followed by a GC/MS analysis, has been set up for the measurement of nucleic acid oxidation products in human urine. For this purpose, isotopically labeled internal standards have been prepared and used for isotope dilution mass spectrometric detection. Using this approach, four oxidized DNA bases, i.e., 5-hydroxyuracil, 5- (hydroxymethyl)uracil, 8-oxo-7,8-dihydroadenine, and 8-oxo-7,8- dihydroguanine, together with 8-oxo-7,8-dihydro-2'-deoxyguanosine have been simultaneously quantified in human urine samples. The levels of the oxidized nucleic acid constituents, as expressed in picomoles per milliliter, were determined to be, in decreasing order: 8-oxo-7,8-dihydroguanine (583 ± 376) > 5-(hydroxymethyl)uracil (121 ± 56) > 5-hydroxyuracil (58 ± 23) > 8-oxo- 7,8-dihydro-2'-deoxyguanosine (30 ± 15) > 8-oxo-7,8-dihydroadenine (7 ± 4). Attempts to determine the amount of 5,6-dihydroxy-5,6-dihydrothymine, 5- hydroxycytosine, and 2,6-diamino-4-hydroxy-5-formamidopyrimidine using the above HPLC-GC/MS method were unsuccessful.